Conformation-Dependent Complexation Interactions for a SMARCA2 PROTAC and Cyclodextrin
Molecular Pharmaceutics · 05.01.2026 · 23 (1) · 561-570
DOI: 10.1021/acs.molpharmaceut.5c01600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 20.12.2025. Verfasst von Matthew N O'Brien Laramy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Synthetic Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States. Hauptthemen laut MEDLINE: Cyclodextrins, Transcription Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Bivalent protein degraders, or proteolysis targeting chimeras (PROTACs), are an emerging therapeutic modality that can be used to drug challenging targets and drive differentiated pharmacology. However, the atypical physicochemical and structural properties of PROTACs can contribute to poor biopharmaceutical properties (e.g., solubility), and complicate drug research and development. To date, there are limited publications on modality-specific formulation strategies to mitigate these liabilities. Herein, we use multiple NMR spectroscopy techniques, isothermal titration calorimetry, and quantitative solubility measurements to study solubilization of a VHL-based PROTAC for SMARCA2, A515. In aqueous solution without solubilizing excipients, we found that A515 exists in two distinct and measurable populations that differ in the rotation of the amide group─a trans-proline rotational isomer that comprises a set of relatively open conformations with larger hydrodynamic size, and a cis-proline rotational isomer with relatively condensed conformations with smaller hydrodynamic size. Upon addition of the solubilizing excipient 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) to A515, we show that the efficiency of ternary host-guest complexation (i.e., the mechanism of solubilization) in each population is distinct and modulated by conformation (i.e., the accessibility of the terminal regions of A515 that are involved in complexation). These observations highlight the unreported and important role of stereochemistry and conformation in the rational formulation design for PROTACs (including solubility enhancement), and suggest specific considerations for VHL-based PROTACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Synthetic Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
- Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
- Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
ORCID-Profile: Matthew N O'Brien Laramy, José G Napolitano, Gennady Khirich, Alberto Gobbi
Zitieren
APA
O'Brien Laramy, M. N., Napolitano, J. G., Zhou, Y., Russell, D. J., Robinson, S., Khirich, G., & Gobbi, A. (2026). Conformation-Dependent Complexation Interactions for a SMARCA2 PROTAC and Cyclodextrin. Molecular Pharmaceutics, 23(1), 561-570. https://doi.org/10.1021/acs.molpharmaceut.5c01600
Vancouver
O'Brien Laramy MN, Napolitano JG, Zhou Y, Russell DJ, Robinson S, Khirich G, et al. Conformation-Dependent Complexation Interactions for a SMARCA2 PROTAC and Cyclodextrin. Molecular Pharmaceutics. 2026;23(1):561-570. doi:10.1021/acs.molpharmaceut.5c01600
BibTeX
@article{OBrienLaramy2026,
author = {O'Brien Laramy, Matthew N and Napolitano, José G and Zhou, Yuhui and Russell, David J and Robinson, Sarah and Khirich, Gennady and Gobbi, Alberto},
title = {Conformation-Dependent Complexation Interactions for a SMARCA2 PROTAC and Cyclodextrin},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {1},
pages = {561--570},
doi = {10.1021/acs.molpharmaceut.5c01600}
}
EUVIMED